Back to results
US 9,867,839 B2Granted
Osteoclast inhibitors for joint conditions
AssigneeAntecip Bioventures II LLC
InventorHerriot Tabuteau
Life of this patent
Estimating the term…
Abstract
Oral dosage forms of osteoclast inhibitors, such as neridronic acid and zoledronic acid, in an acid or a salt form, can be used to treat or alleviate pain or related conditions, such as joint conditions.
Claims30
A method of treating pain associated with a joint comprising:
- administering neridronic acid in an acid form or a salt form to a patient who has suffered for at least 3 months with 1) pain associated with a joint and 2) a pain intensity of 5 or greater measured using the 0-10 numerical rating scale (NRS) or 5 cm or greater using the 10 cm visual analog scale (VAS).
A method of treating pain associated with a joint comprising:
- orally administering zoledronic acid in an acid form or a salt form to a patient having 1) pain associated with a joint and 2) a pain intensity of 5 or greater measured using the 0-10 NRS or 5 cm or greater using the 10 cm VAS, wherein a total of about 400 mg to about 600 mg of zoledronic acid is administered in 2 or 3 individual doses within a period of about a month.
Dependencies are inferred from the claim text.